Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated July 26, 2024, titled "Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 U.S. FDA Approves LEQSELVI (deuruxolitinib)".